Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer’s Disease

ANAVEX 2-73 trial to be initiated immediately in Germany Hoboken, NJ — March 15, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL)  today announced that its clinical trial application (CTA) for ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease, has been approved by the German regulatory health authority, BfArM.  The Phase I trial…